Press Releases

Date Title
Toggle Summary Kura Oncology to Report Fourth Quarter and Full Year 2017 Financial Results
SAN DIEGO , March 05, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report fourth quarter and full year 2017 financial results after the close of
Toggle Summary Kura Oncology Provides Update on Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Cancer
– Confirmed partial responses observed in five of six evaluable patients with HRAS mutant HNSCC – – Rate of enrollment increasing with three additional patients enrolled in four months – – Initiation of registrational trial in HRAS mutant HNSCC anticipated this year – SAN DIEGO , Feb.
Toggle Summary Kura Oncology to Present at the Leerink Partners 7th Annual Global Healthcare Conference
SAN DIEGO , Feb. 08, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced its participation in the Leerink Partners 7th Annual Global Healthcare Conference.
Toggle Summary Kura Oncology Added to Nasdaq Biotechnology Index
SAN DIEGO , Dec. 18, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it has been selected for addition to the Nasdaq Biotechnology Index (Nasdaq:NBI),
Toggle Summary Kura Oncology Identifies Potential Biomarkers of Activity for Lead Candidate Tipifarnib in Bone Marrow Cancers
CXCR4/CXCR2 expression ratio and bone marrow homing of myeloid cells identified as potential markers for tipifarnib in MDS, AML and CMML CXCL12/CXCR4 pathway a potential therapeutic target of farnesyl transferase inhibitors Findings support development of tipifarnib in certain bone marrow cancers
Toggle Summary Kura Oncology Reports Positive Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia
– Primary objective met with three objective responses in nine patients with RAS wild-type tumor status (33%), two additional RAS wild-type patients pending best response evaluation – – All nine evaluable patients with RAS wild-type achieved stable disease or better – – Preliminary data presented
Toggle Summary Kura Oncology to Host Investor Day on November 16, 2017
SAN DIEGO , Nov. 09, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. , (Nasdaq:KURA) a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will host an Investor Day on Thursday, November 16, 2017 , from 8:30 a.m.
Toggle Summary Kura Oncology Reports Third Quarter 2017 Financial Results and Provides Corporate Update
Management to host webcast and conference call today at 4:30 p.m. ET SAN DIEGO , Nov. 07, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. , (Nasdaq:KURA) a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today reported third quarter 2017
Toggle Summary Kura Oncology Announces Upcoming Presentations at American Society of Hematology Annual Meeting
SAN DIEGO , Nov. 01, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that four abstracts relating to the Company’s lead product candidate, tipifarnib, have been
Toggle Summary Kura Oncology to Report Third Quarter 2017 Financial Results
SAN DIEGO , Oct. 31, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report third quarter 2017 financial results after the close of U.S.